Amber Clemmons, Pharm.D., BCOP

Clinical and Administrative Pharmacy, Augusta
Clinical Associate Professor

Clinical and Administrative Pharmacy, Augusta

Education

Doctor of Pharmacy , University of Michigan College of Pharmacy 2009

PGY1 Pharmacy Practice Residency , MCG Health 2009-2010

PGY2 Hematology/Oncology Specialty Residency , University of North Carolina Hospitals 2010-2011

Adjunct Clinical Instructor , UNC Eshelman School of Pharmacy 2010-2011

Clinical Assistant Professor , UGA College of Pharmacy 2011-2016

Clinical Associate Professor, UGA College of Pharmacy 2016-Present

Honors, Awards, and Achievements

New Practitioner Award, Hematology/Oncology Pharmacy Association (HOPA) – 2017

Augusta University’s Educational Innovation Institute (EII) Health Sciences Educational Research Scholarship Award –2016

UGA College of Pharmacy’s Teacher of the Year – 2016

Chair of the Program Committee for the Hematology/Oncology Pharmacy Association (HOPA) – 2015- 2016

GSHP Young Health System Pharmacist of the Year – 2014

First recipient of the ASBMT Pharmacy SIG New Practitioner Award – 2014

Board Certified Oncology Pharmacist (BCOP) – 2012-current

STaR Young Investigator of the Year – 2011

High Academic Honors Graduate, University of Michigan – 2009

Rho Chi Academic Honor Society, University of Michigan – 2008

Affiliations
Research Interests

My research interests are Supportive Care, Hematologic Malignancies, Adult Bone Marrow Transplantation, and Scholarship of Teaching and Learning.

Selected Publications

Presentations

“The FONDO Clinical Trial” Platform Completed Research Presentation.  HOPE Annual Conference. 2018.

Treatment Updates for Acute Myeloid Leukemia. 1-hour ACPE Accredited Continuing Education Program. HOPA webinar. December 2017.

Significant Papers in Hematology/Oncology. 1-hour ACPE Accredited Continuing Educational Program. HOPA Annual Meeting. March 2017.

Presented 1hr ACPE lecture “Immunology: Looking Back, Moving Forward” and the 2015 Summer Georgia Society of Health System Pharmacy meeting in Amelia Island, Florida

Presented “Anti-emesis in HCT” at the 2014 Fundamentals of Hematopoietic Stem Cell Transplantation (HSCT) Training Course in Grapevine, Texas

Presented 1hr ACPE lecture “New Drug Update” at the BMT Tandem Meetings – Pharmacist Conference in Salt Lake City, Utah. 2013.

Publications

Clemmons AB, Orr J, Andrick B, Gandhi A, Sportes S, Deremer D. Randomized, placebo-controlled, phase III trial of fosaprepitant, ondansetron, dexamethasone (FOND) versus FOND plus olanzapine (FOND-O) for the prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancies receiving highly emetogenic chemotherapy and hematopoietic cell transplantation regimens: the FOND-O Trial. Biol Blood Marrow Transplant. Accepted June 2018. In Press.

Clemmons AB, Alexander M, DeGregory K, Kennedy L. The Hematopoietic Cell Transplant Pharmacist: Roles, Responsibilities, and Recommendations from the ASBMT Pharmacy SIG. Biol Blood Marrow Transplant. Dec 2017. DOI: 10.1016/j.bbmt.2017.12.803

Clemmons AB, Bech C, Pantin J, Ahmad I. Acute Kidney Injury in Hematopoietic Cell Transplantation Patients Receiving Vancomycin and Piperacillin/Tazobactam versus Vancomycin and Cefepime Biology of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. Dec 2017. DOI:10.1016/j.bbmt.2017.12.799

Clemmons AB, Gandhi A, Albrecht B, Jacobson S, Pantin J. Impact of Fluoroquinolone Prophylaxis on Infectious Related Outcomes after Hematopoietic Cell Transplantation. Journal of Oncology Pharmacy Practice. 2017; DOI: 10.1177/1078155217735153.

McCaleb R, Shah A, Clemmons AB. Clinical outcomes of acid suppressive therapy use in hematology/oncology patients at an academic medical center. Annals of Pharmacotherapy. E-pub ahead of print April 2016.

Clemmons AB, Anderegg S. Mixed outpatient-inpatient autologous stem cell transplant for multiple myeloma: A cost-saving initiative in a resource constrained environment. Journal of Oncology Pharmacy Practice. E-pub ahead of print March 21 2016.

Deremer D, Clemmons AB, Orr J, Clark S, Gandhi A. Emerging role of olanzapine in the armamentarium for chemotherapy induced nausea and vomiting (CINV). Pharmacotherapy. 2016; 36 (2): 218-229.

Hartranft M, Clemmons AB, Deremer D, Kota V. Evaluation of romiplostim for the treatment of secondary failure of platelet recovery among allogeneic hematopoietic stem cell transplant patients. Journal of Oncology Pharmacy Practice. E-pub ahead of print. October 2015.

Clemmons AB, Hoge S, Cribb A, Manasco K. Development and implementation of a writing program to improve resident authorship rates. American Journal of Health-System Pharmacy. 2015; 72:S53-S57.

Evans S, Clemmons AB. Obinutuzumab: A novel anti-CD20 monoclonal antibody for chronic lymphocytic leukemia. Journal of the Advanced Practitioner in Oncology. July 2015;6:370–374.

Clark S, Clemmons AB, et al. Fosaprepitant for the prevention of nausea and vomiting in patients receiving BEAM or high-dose melphalan before autologous hematopoietic stem cell transplant. Journal of Oncology Pharmacy Practice. E-pub ahead of print May 2015.

Kota V, Clemmons AB, et al. Congestive heart failure during induction with anthracycline based therapy in patients with acute promyelocytic leukemia may be more frequent than expected. Journal of Community and Supportive Oncology (JCSO). Nov 2014;12:390-393.

Clemmons AB, Evans S, Deremer D, Awan F. Busulfan dosing (Q6 or Q24) with adjusted or actual body weight, does it matter? Journal of Oncology Pharmacy Practice. E-pub ahead of print July 1, 2014.

Clemmons AB, Hartranft M†, et al. Administration of anti-thymocyte globulin: A comparison of two protocols. Bone Marrow Transplantation. E-pub ahead of print August 4, 2014.

Clemmons AB, Ensley E, Hoge S, Clark S. Fixed-dose rasburicase in overweight and obese patients versus normal weight patients. Annals of Pharmacotherapy. E-pub ahead of print July 17 2014.

Neville M, Clemmons AB, Hunter C. Application of opiate analgesia concepts in a third year skills laboratory on three campuses. Journal of Pain and Palliative Care Pharmacotherapy. 2014; March; 28(1):10-18.

Bradley AM, Devine M, DeRemer D. Brentuximab vedotin: a novel anti-CD30 antibody drug conjugate.American Journal of Health-System Pharmacy. 2013; Apr 1; 70(7): 589-97. DOI: 10.2146/ajhp110608.

Bradley AM, Valgus J, Bernard S. Converting to transdermal fentanyl: Avoidance of under-dosing. Journal of Palliative Medicine. 2013; Mar 11. DOI:10.1089/jpm.2012.0424.

Bradley AM. Anti-Emesis in HCT. Chapter in: Fundamentals of Hematopoietic Stem Cell Transplantation Training Course. ASBMT Pharmacy SIG. 1st Edition in February 2013. Revised 2nd Edition in February 2014.

DeRemer D, Katsanevas K, Bradley AM, Awan F. Romiplostim resistance in secondary failure of platelet recovery (SFPR). Journal of Oncology Pharmacy Practice. 2013; 19(4) 369–372.

Bradley AM, Deal A, Buie L, van Deventer H. Neutropenia-associated outcomes in adults with acute myeloid leukemia receiving cytarabine consolidation chemotherapy with or without granulocyte colony-stimulating factor. Pharmacotherapy. 2012; Dec; 32(12): 1070-7.

Bradley AM, Buie LW, Kuykendal A, Voorhees P. Successful utilization of intrathecal carboxypeptidase-G2 for intrathecal methotrexate overdose: A case study and review of the literature. Clinical Lymphoma Myeloma & Leukemia. 2012; Oct 16.

Manasco KB, Bradley AM, Gomez TA. A survey of learning opportunities in academia for pharmacy residents. American Journal of Health-System Pharmacy. August 15, 2012; 69(16): 1410-1414.

Ku P, Clemmons AB, Waller J, Sportes S. Prolonged versus short infusion rates for intravenous magnesium sulfate administration in hematopoietic cell transplant patients. Support Care Cancer DOI :10.1007/s00520-018-4127-z.

Grant Support

Randy Ellison Cancer Research Fund – 2014
Translation Research Initative Grant – 2013
Earl and Carole Wright Advanced Education Program for Cancer – 2011, 2012 and 2018